Compare HURA & IPEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HURA | IPEX |
|---|---|---|
| Founded | 2009 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 123.4M |
| IPO Year | N/A | N/A |
| Metric | HURA | IPEX |
|---|---|---|
| Price | $1.64 | $10.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 18.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $41.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $10.25 |
| 52 Week High | $4.41 | $10.39 |
| Indicator | HURA | IPEX |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 52.40 |
| Support Level | $1.56 | N/A |
| Resistance Level | $2.68 | $10.35 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 74.71 | 50.00 |
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Inflection Point Acquisition Corp V is a blank check company.